Cite
MLA Citation
Jagdeep Nanchahal et al.. “Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.” Lancet, vol. 4, 2022, pp. e407–e416. http://access.bl.uk/ark:/81055/vdc_100155167892.0x000002